PHC Holdings Corporation
6523・Prime Market・Electric Appliances
Business
PHC Holdings is a healthcare-focused holding company comprising 16 domestic subsidiaries and 63 overseas subsidiaries. It operates three main domains: "Diabetes Management," which deploys Blood Glucose Monitoring (BGM) Systems in over 90 countries worldwide; "Healthcare Solutions," which provides clinical laboratory testing, medical IT, and drug discovery support within Japan; and "Diagnostics & Life Sciences," which deploys pathology, biomedica, and diagnostic reagent equipment globally. Consolidated revenue for FY2026 (ending March 2026) is ¥364,403 million. The company's main customers are medical institutions, pharmacies, research institutions, and pharmaceutical companies, and its business structure combines equipment sales with recurring sales of consumables.
Business Model
In the Diabetes Management domain, the company sells blood glucose monitoring system units and adopts a recurring model that generates stable revenue through ongoing purchases of consumables such as sensors. In Healthcare Solutions, continuous revenue is secured through implementation and maintenance services for electronic medical record and medical claims (reception) systems, as well as clinical laboratory testing services. In Diagnostics & Life Sciences, in addition to sales of pathology equipment and Biomedica equipment, revenue is supplemented by consumables, reagents, and maintenance services. The adjusted EBITDA for the three domains combined was ¥51,959 million (FY2026 (ending March 2026)).
Company Strengths
The company possesses an efficient production system based on patented biosensing technology and its own designed manufacturing lines. The BGM "CONTOUR Series" is provided to approximately 10 million patients in over 90 countries worldwide, and an extensive global distribution infrastructure has been established through ADC's sales subsidiary network. In FY2026 (ending March 2026), Diabetes Management revenue was ¥101,581 million, and operating profit was ¥20,085 million (up 44.6% year on year).
The company leverages multiple core technologies—sensor technology, cryopreservation technology, digital pathology, and cell culture control technology—across domains. R&D expenses in FY2026 (ending March 2026) were ¥10,914 million. The company has a track record of bringing new products to practical use, including the in-house development and launch of the automated cell culture device "LiCellGrow" and obtaining domestic manufacturing and marketing approval for the "E1000 Dx Digital Pathology Solution." Based on the Medium-Term Management Plan 2027, a cross-domain R&D organization has been newly established to strengthen the development structure.
WHITE MEXX (WMX) offers integrated electronic medical record systems with receipt computer functions for clinics and electronic medication history systems for pharmacies, providing consistent support from installation through adoption at over 180 service sites nationwide. The cumulative number of installations of electronic prescription management software exceeds 20,000. The company has newly launched the cloud-based electronic medical record system "Medicom Cloud Karte," establishing an infrastructure to respond to demand for medical DX.
ENVALITH's Perspective
Performance Trend
Revenue for FY2026 (ending March 2026) was ¥364,403 million (up 0.8% year on year), maintaining moderate growth. Operating profit was ¥22,688 million (up 0.5% year on year), remaining flat, but due to an external factor—a foreign exchange loss of ¥10,472 million (compared with a gain of ¥1,151 million in the same period of the prior year)—profit before tax fell sharply to ¥6,390 million (down 66.1% year on year), and profit attributable to owners of the parent plunged to ¥492 million (down 95.3% year on year). Adjusted EBITDA, which reflects underlying performance, improved to ¥51,959 million (up 3.7% year on year), indicating that the effects of structural reforms are continuing. Looking at the trend over the past five fiscal years, the company moved from losses in FY2022, FY2023, and FY2024 to profitability in FY2025, and in FY2026 profit was significantly compressed due to foreign exchange factors. For FY2027 (ending March 2027), the company expects a substantial recovery in net income to ¥15,400 million, assuming the foreign exchange loss does not recur.
Growth Strategy
Advancing the medium-term plan around three pillars: strengthening the earnings base, optimizing the business portfolio, and improving the financial structure
Continuing initiatives to raise unit prices and increase sales volumes in the BGM business, absorbing the impact of market contraction in developed countries. In January 2026, the company transferred the CGM business (Eversense) to Senseonics Holdings, Inc., discontinuing an unprofitable business. For FY2027 (ending March 2027), while expecting to expand market share in Europe and the US, revenue is projected at ¥92,300 million (down 9.1% year on year) due to the decline in sales from the CGM transfer and the impact of yen appreciation, while operating profit is expected at ¥24,000 million (up 19.5% year on year).
In the LSIM Business (Clinical Laboratory Testing Services), the company continues growth initiatives in the genetic and genomic testing field, achieving revenue growth by containing the impact of an inappropriate incident more than initially expected. The Healthcare IT Solutions Business is promoting sales expansion measures to capture demand for migration to cloud-based electronic medical records. The CRO Business (Drug Discovery Support) aims for recovery through strengthened order-taking activities. For FY2027 (ending March 2027), revenue is forecast at ¥132,100 million (up 2.9% year on year) and operating profit at ¥6,500 million (up 4.3% year on year).
Continuing cost reductions through the effects of price revisions in the Pathology Business (Epredia) and optimization of production sites. The Biomedica Business division and the Diagnostic Reagents Business division will be integrated to form a Life Sciences Business division (effective from FY2027, ending March 2027). The Indonesian B to B business will be transferred from Headquarters & Others to Diagnostics & Life Sciences (expected revenue impact of +¥4.4 billion). For FY2027 (ending March 2027), revenue is forecast at ¥135,200 million (up 5.4% year on year) and operating profit at ¥4,900 million (up 25.9% year on year).
The current medium-term management plan (through fiscal year 2027) prioritizes strengthening the financial base, continuing steady repayment of borrowings. Borrowings at the end of FY2026 (ending March 2026) decreased by ¥20,702 million compared to the end of the previous fiscal year, and the equity attributable to owners of the parent ratio improved to 29.8% (from 26.6% in the previous year). The annual dividend per share is maintained at ¥42 (the same amount is also forecast for FY2027, ending March 2027). The policy is to aim for stable growth in both business expansion and shareholder returns under the next medium-term management plan.
Last updated: July 19, 2026